Shares of Novavax (NVAX.US) are slumping over 20% today, putting an abrupt end to an upward correction that has pushed the company's share 50% higher in a matter of days. Company reported Q4 2023 earnings report today before opening of the Wall Street session, which included disappointing full-year forecasts.
Novavax reported an 18% YoY drop in Q4 revenue to $291.3 million, significantly below $322 million expected by analysts. The company's only marketable product is its Covid vaccine, for which the demand has been dropping as the world puts pandemic in the rearview mirror. Nevertheless, Novavax managed to narrow the loss compared to a year ago quarter.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appApart from weakish Q3 2023 results, 2024 forecasts provided by the company are also playing a role in today's share price collapse. Company expects 2024 revenue to reach $800 million to $1 billion. This translates into mid-point of $900 million, below $970 million expected by analysts. Moreover, it also means that Novavax expects a flat to slightly lower revenue this year.
Q4 2023 earnings
- Revenue: $291.3 million vs $322.2 million expected (-18% YoY)
- Research & Development expenses: $164.7 million vs $136.1 million expected (-36% YoY)
- Net loss: $178.4 million vs $23.9 million expected
- EPS: -$1.44 vs -$0.43 expected (-$2.28 a year ago)
- Cash position: $568.5 million vs $515 million expected
2023 results
- Revenue: $984 million vs $2 billion in 2022
- Research & Development expenses: $738 million vs $1.2 billion in 2022
- Net loss: $545 million vs $658 million in 2022
Full-year forecast
- Revenue: $0.80-1.00 billion vs $0.97 billion expected
- Research & Development expenses: $700-800 million
Taking a look at Novavax chart (NVAX.US) at D1 interval, we can see that the stock jumped over 50% between February 21 and February 27, 2024. Stock was trading 70% above early-February lows at the close of the Wall Street session yesterday. However, disappointing earnings releases triggered a massive share price slump today. Stock launched today's trading over 20% lower and deepened those declines to trade almost 30% lower on the day now. The $4.30 swing area is being tested at press time.
Source: xStation5
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
